Table 2.

Results of KIR ligand incompatibility and outcome in recent clinical trials with non-HLA identical sibling stem cell transplants.

Relapse % KIR IncompatibleGVHD II–IV % KIR IncompatibleDFS % KIR Incompatible
GroupDonorPatient (n)YesNoYesNoYesNo
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; DFS, disease-free survival; GVHD, graft-versus-host disease; haplo ID, haploidentical T cell depleted transplants; KIR, killer immunoglobulin-like receptors; MDS, myelodysplastic syndrome; SCT, stem cell transplantation; URD, unrelated donor transplant; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease 
* (bold figures) significance at least P < .01 
** 5-year survivial. 
‡ (bold figures) P = .07 
Perugia7  Haplo AML (57) 0** 75 13.7 60 5** 
 ID ALL (35) 85 90     
Minnesota26  URD Various (175)
 (CML, ALL, AML, MDS, nonmalignant) 12 61 50 32 40** 
Multicenter15 URD Various (135)
 (ALL, AML, CML, MDS, NHL, HD, MM) 6 21‡ 30 40 87 39* 
Relapse % KIR IncompatibleGVHD II–IV % KIR IncompatibleDFS % KIR Incompatible
GroupDonorPatient (n)YesNoYesNoYesNo
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; DFS, disease-free survival; GVHD, graft-versus-host disease; haplo ID, haploidentical T cell depleted transplants; KIR, killer immunoglobulin-like receptors; MDS, myelodysplastic syndrome; SCT, stem cell transplantation; URD, unrelated donor transplant; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease 
* (bold figures) significance at least P < .01 
** 5-year survivial. 
‡ (bold figures) P = .07 
Perugia7  Haplo AML (57) 0** 75 13.7 60 5** 
 ID ALL (35) 85 90     
Minnesota26  URD Various (175)
 (CML, ALL, AML, MDS, nonmalignant) 12 61 50 32 40** 
Multicenter15 URD Various (135)
 (ALL, AML, CML, MDS, NHL, HD, MM) 6 21‡ 30 40 87 39* 

or Create an Account

Close Modal
Close Modal